Stig Palm

Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

OPTILATER: optimal long-term survival after cancer - a cross-sectional study protocol for a quantitative survey on the care situation of long-term cancer survivors in Germany.

OPTILATER: optimal long-term survival after cancer - a cross-sectional study protocol for a quantitative survey on the care situation of long-term cancer survivors in Germany.

Journal: BMC cancer
Published: July 18, 2025

A Novel Method for Real-Time Quantification of Radioligand Binding to Living Tumor Cells In Vitro.

A Novel Method for Real-Time Quantification of Radioligand Binding to Living Tumor Cells In Vitro.

Journal: Cancer biotherapy & radiopharmaceuticals
Published: January 24, 2024

A proposed production method for astatinated (At-211) Trastuzumab for use in a Phase I clinical trial.

A proposed production method for astatinated (At-211) Trastuzumab for use in a Phase I clinical trial.

Journal: PloS one
Published: October 16, 2023

Astatine-211 based radionuclide therapy: Current clinical trial landscape.

Astatine-211 based radionuclide therapy: Current clinical trial landscape.

Journal: Frontiers in medicine
Published: October 21, 2022

Impact of radiopharmaceutical therapy (177Lu, 225Ac) microdistribution in a cancer-associated fibroblasts model.

Impact of radiopharmaceutical therapy (177Lu, 225Ac) microdistribution in a cancer-associated fibroblasts model.

Journal: EJNMMI physics
Published: June 03, 2022

Estimating the Risk for Secondary Cancer After Targeted α-Therapy with 211At Intraperitoneal Radioimmunotherapy.

Estimating the Risk for Secondary Cancer After Targeted α-Therapy with 211At Intraperitoneal Radioimmunotherapy.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: October 08, 2021

Evaluation of therapeutic efficacy of 211At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer.

Evaluation of therapeutic efficacy of 211At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer.

Journal: Translational oncology
Published: April 16, 2020

Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure.

Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure.

Journal: Cancer biotherapy & radiopharmaceuticals
Published: February 21, 2020

Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors.

Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors.

Journal: EJNMMI research
Published: November 18, 2019

ICRP Publication 140: Radiological Protection in Therapy with Radiopharmaceuticals.

ICRP Publication 140: Radiological Protection in Therapy with Radiopharmaceuticals.

Journal: Annals of the ICRP
Published: October 01, 2019

Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.

Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.

Journal: Molecular pharmaceutics
Published: July 04, 2019

Towards elucidating the radiochemistry of astatine - Behavior in chloroform.

Towards elucidating the radiochemistry of astatine - Behavior in chloroform.

Journal: Scientific reports
Published: June 04, 2019
Showing 1-12 of 24

Last Updated: 09/26/2026